Cognitive disorder evaluation-focused developer Neuronetrix has raised $2 million in a new round of equity financing, according to a recently posted SEC filing.
Money in the round came from eight anonymous investors, with the first sale noted on February 3.
The Louisville, Ky.-based company is looking for an additional $3 million before closing the round, according to the filing.
The company produces the FDA-cleared Cognision objective biomarker system designed to aid neurologists and physicians in differentiating between dementia and depression during diagnosis. The system also allows physicians to track disease progression and understand cognitive deficits associated with dementia and concussion or traumatic brain injuries, according to its website.
Neuronetrix has not yet stated how it plans to spend funds raised in the round.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.